Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Abstract Background Targeting receptor-interacting serine/threonine protein kinase 1 could mitigate the devastating sequelae of the hyperinflammatory state observed in severe cases of COVID-19. This study explored the immunomodulatory and clinical effects of the receptor-interacting serine/threonine...

Full description

Bibliographic Details
Main Authors: Pierre-Francois Clot, Christine Farenc, Benjamin T. Suratt, Tillmann Krahnke, Agnes Tardat, Peter Florian, Robert Pomponio, Naimish Patel, Maria Wiekowski, Yong Lin, Benjamin Terrier, Heribert Staudinger
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Respiratory Research
Subjects:
Biomarker
Inflammation
Immunomodulatory
Receptor-interacting serine/threonine protein kinase 1
COVID-19
Online Access:https://doi.org/10.1186/s12931-024-02670-z

Internet

https://doi.org/10.1186/s12931-024-02670-z

Similar Items